Your generous gifts have a life-changing impact on cancer research and patient care.
Donors help speed the pace of research by acting as seed funding for new projects that may not otherwise receive funding. In turn, that support fuels new breakthroughs in research and funds compassionate patient care programs.
Check out these recent advancements made possible with donor support:
- An innovative brain cancer vaccine, SurVaxM, developed at Roswell Park, has shown great success in treating adult patients with advanced brain cancer. Researchers are now studying different ways to use SurVaxM, with four studies underway:
- The phase 2B SURVIVE trial in adults with newly diagnosed glioblastoma at 11 U.S. sites.
- A pilot study in children, conducted by the NCI-funded Pediatric Brain Tumor Consortium with participation from Roswell Park and 13 other North American centers, studies some forms of pediatric medulloblastoma, high-grade glioma, ependymoma and newly diagnosed diffuse intrinsic pontine glioma.
- A phase 1 study in adults with multiple myeloma, in combination with lenalidomide maintenance therapy, was fully accrued at Roswell Park.
- A phase 1 study in adults with neuroendocrine tumors.
- A prestigious research initiative will study new applications for CAR T-cell therapy, which has shown great promise in treating liquid cancers. Research will now delve into using CAR T-cell therapy to treat small cell lung cancer, prostate cancer, ovarian cancer, pancreatic cancer, and adult and pediatric sarcomas.
- Essential quality-of-life programs have been established for Roswell Park patients and their families
- New research projects were identified as having the most potential to make a difference in the future of cancer care.
To learn about our funding process, visit the financials and stewardship page.